Abstract
Allergic rhinitis (AR) is an immune-mediated inflammatory condition characterized by immune cell infiltration of the nasal mucosa, with symptoms of rhinorrhea, sneezing, nasal obstruction, and itchiness. Currently, common medication for AR is anti-inflammatory treatment including intranasal steroids, oral, or intranasal anti-histamines, and immunotherapy. These strategies are effective to the majority of patients with AR, but some patients under medication cannot achieve symptom relieve and suffer from bothersome side effects, indicating a demand for novel anti-inflammatory treatment as alternatives. Chemokines, a complex superfamily of small, secreted proteins, were initially recognized for their chemotactic effects on various immune cells. Chemokines constitute both physiological and inflammatory cell positioning systems and mediate cell localization to certain sites via interaction with their receptors, which are expressed on responding cells. Chemokines and their receptors participate in the sensitization, early phase response, and late phase response of AR by promoting inflammatory cell recruitment, differentiation, and allergic mediator release. In this review, we first systemically summarize chemokines and chemokine receptors that are important in AR pathophysiology and then discuss potential strategies targeting chemokines and their receptors for AR therapy.
Similar content being viewed by others
References
Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G et al (2020) Allergic rhinitis. Nat Rev Dis Primers 6:95. https://doi.org/10.1038/s41572-020-00227-0
Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al (2015) Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg 152:S1-43. https://doi.org/10.1177/0194599814561600
Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW et al (2020) Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol 145:70-80.e3. https://doi.org/10.1016/j.jaci.2019.06.049
Droessaert V, Timmermans M, Dekimpe E, Seys S, Ceuppens JJ, Fokkens WJ et al (2016) Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy. Rhinology 54:214–220. https://doi.org/10.4193/Rhino14.282
Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK et al (2009) Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 124:S43-70. https://doi.org/10.1016/j.jaci.2009.05.013
Moser B, Wolf M, Walz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25:75–84. https://doi.org/10.1016/j.it.2003.12.005
Schall TJ, Proudfoot AE (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11:355–363. https://doi.org/10.1038/nri2972
Zheng J, Zeng M, Nian JB, Zeng LY, Fu Z, Huang QJ et al (2020) The CXCR4/miR-125b/FoxP3 axis regulates the function of the epithelial barrier via autophagy in allergic rhinitis. Am J Transl Res 12:2570–2584
Liu C, Zhang X, Xiang Y, Qu X, Liu H, Liu C et al (2018) Role of epithelial chemokines in the pathogenesis of airway inflammation in asthma (Review). Mol Med Rep 17:6935–6941. https://doi.org/10.3892/mmr.2018.8739
Kim B, Yeon JW, Lee JH, Lee HJ, Byun J, Lee K (2020) CCL2 mitigates cyclic AMP-suppressed Th2 immune response in human dendritic cells. Allergy 75:2108–2111. https://doi.org/10.1111/all.14284
Hirata H, Yukawa T, Tanaka A, Miyao T, Fukuda T, Fukushima Y et al (2019) Th2 cell differentiation from naive CD4(+) T cells is enhanced by autocrine CC chemokines in atopic diseases. Clin Exp Allergy 49:474–483. https://doi.org/10.1111/cea.13313
Burks AW, Holgate ST, O’Hehir RE, Bacharier LB, Broide DH, Hershey GK et al (2019) Middleton’s allergy E-Book: principles and practice. Elsevier, Edinburgh
Romagnani S (2002) Cytokines and chemoattractants in allergic inflammation. Mol Immunol 38:881–885. https://doi.org/10.1016/s0161-5890(02)00013-5
Wang D, Smitz J, Waterschoot S, Clement P (1997) An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge. Allergy 52:162–167. https://doi.org/10.1111/j.1398-9995.1997.tb00970.x
Miyazaki D, Nakamura T, Toda M, Cheung-Chau KW, Richardson RM, Ono SJ (2005) Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J Clin Invest 115:434–442. https://doi.org/10.1172/jci18452
Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY, Kaplan AP (1992) RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 149:636–642
Castellani ML, De Lutiis MA, Toniato E, Conti F, Felaco P, Fulcheri M et al (2010) Impact of RANTES, MCP-1 and IL-8 in mast cells. J Biol Regul Homeost Agents 24:1–6
Pawankar R, Mori S, Ozu C, Kimura S (2011) Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy 1:157–167. https://doi.org/10.5415/apallergy.2011.1.3.157
Blanchard C, Rothenberg ME (2009) Biology of the eosinophil. Adv Immunol 101:81–121. https://doi.org/10.1016/s0065-2776(08)01003-1
Pease JE (2006) Asthma, allergy and chemokines. Curr Drug Targets 7:3–12. https://doi.org/10.2174/138945006775270204
Dai M, Zhu X, Yu J, Yuan J, Zhu Y, Bao Y et al (2022) CCR3 gene knockout in bone marrow cells ameliorates combined allergic rhinitis and asthma syndrome (CARAS) by reducing airway inflammatory cell infiltration and Th2 cytokines expression in mice model. Int Immunopharmacol 104:108509. https://doi.org/10.1016/j.intimp.2021.108509
Perić A, Sotirović J, Špadijer-Mirković C, Matković-Jožin S, Perić AV, Vojvodić D (2016) Nonselective chemokine levels in nasal secretions of patients with perennial nonallergic and allergic rhinitis. Int Forum Allergy Rhinol 6:392–397. https://doi.org/10.1002/alr.21684
Yi S, Zhai J, Niu R, Zhu G, Wang M, Liu J et al (2018) Eosinophil recruitment is dynamically regulated by interplay among lung dendritic cell subsets after allergen challenge. Nat Commun 9:3879. https://doi.org/10.1038/s41467-018-06316-9
Chen Y, Yang M, Deng J, Wang K, Shi J (2020) Elevated levels of activated and pathogenic eosinophils characterize moderate-severe house dust mite allergic rhinitis. J Immunol Res 2020:8085615. https://doi.org/10.1155/2020/8085615
Perić A, Mirković C, Đurđević BV, Perić AV, Vojvodić D (2017) Eosinophil chemokines and Clara cell protein 16 production in nasal mucosa of patients with persistent allergic rhinitis. Eurasian J Med 49:178–182. https://doi.org/10.5152/eurasianjmed.2017.17203
Špadijer Mirković C, Perić A, Vukomanović Đurđević B, Vojvodić D (2017) Effects of fluticasone Furoate nasal spray on parameters of eosinophilic inflammation in patients with nasal polyposis and perennial allergic rhinitis. Ann Otol Rhinol Laryngol 126:573–580. https://doi.org/10.1177/0003489417713505
Koya T, Takeda K, Kodama T, Miyahara N, Matsubara S, Balhorn A et al (2006) RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge. Am J Respir Cell Mol Biol 35:147–154. https://doi.org/10.1165/rcmb.2005-0394OC
Zhang RX, Yu SQ, Jiang JZ, Liu GJ (2007) Complementary DNA microarray analysis of chemokines and their receptors in allergic rhinitis. J Investig Allergol Clin Immunol 17:329–336
de Campos L, Galvão CES, Mairena EC, Voegels R, Kalil J, Castro FM et al (2019) Increased gene expression of inflammatory markers in nasal turbinate of patients with persistent allergic rhinitis and chronic obstruction. Eur Arch Otorhinolaryngol 276:3247–3249. https://doi.org/10.1007/s00405-019-05581-8
Azazi EA, Bakir SM, Mohtady HA, Almonem AA (2007) Circulating chemokine eotaxin and chemokine receptor CCR3 in allergic patients. Egypt J Immunol 14:73–82
Berghi NO, Dumitru M, Vrinceanu D, Ciuluvica RC, Simioniuc-Petrescu A, Caragheorgheopol R et al (2020) Relationship between chemokines and T lymphocytes in the context of respiratory allergies (review). Exp Ther Med 20:2352–2360. https://doi.org/10.3892/etm.2020.8961
Tworek D, Kuna P, Młynarski W, Górski P, Pietras T, Antczak A (2013) MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis. Arch Med Sci 9:849–853. https://doi.org/10.5114/aoms.2013.37198
Banfield G, Watanabe H, Scadding G, Jacobson MR, Till SJ, Hall DA et al (2010) CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses. Allergy 65:1126–1133. https://doi.org/10.1111/j.1398-9995.2010.02327.x
Yu X, Wang M, Cao Z (2020) Reduced CD4(+)T cell CXCR3 expression in patients with allergic rhinitis. Front Immunol 11:581180. https://doi.org/10.3389/fimmu.2020.581180
Pirayesh A, Ferdosi S, Shirzad H, Amani S, Bahadivand Chegini H, Bagheri N et al (2018) Differential expression of CCL18 in moderate/severe and mild persistent allergic rhinitis and its correlation with disease parameters. J Immunoassay Immunochem 39:485–495. https://doi.org/10.1080/15321819.2018.1506931
Sadeghi HR, Pirayesh A, Shahsavan S, Amani S, Amini SA, Samani KG et al (2020) Correlation of acidic mammalian chitinase expression with disease severity in patients with moderate/severe persistent allergic rhinitis. Cent Eur J Immunol 45:294–300. https://doi.org/10.5114/ceji.2020.101251
Miao M, De Clercq E, Li G (2020) Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol 16:11–30. https://doi.org/10.1080/17425255.2020.1711884
Gauthier M, Kale SL, Oriss TB, Scholl K, Das S, Yuan H et al (2022) Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation. J Allergy Clin Immunol 149:113-124.e7. https://doi.org/10.1016/j.jaci.2021.05.044
Zou LP, Wang LX, Zhang Y, Du WL (2011) Expression of SDF-1 in lung tissues and intervention of AMD3100 in asthmatic rats. Zhongguo Dang Dai Er Ke Za Zhi 13:321–325
Sakai H, Yabe S, Sato K, Kai Y, Sato F, Yumoto T et al (2018) ELR(+) chemokine-mediated neutrophil recruitment is involved in 2,4,6-trinitrochlorobenzene-induced contact hypersensitivity. Clin Exp Pharmacol Physiol 45:27–33. https://doi.org/10.1111/1440-1681.12839
Keglowich L, Roth M, Philippova M, Resink T, Tjin G, Oliver B et al (2013) Bronchial smooth muscle cells of asthmatics promote angiogenesis through elevated secretion of CXC-chemokines (ENA-78, GRO-α, and IL-8). PLoS ONE 8:e81494. https://doi.org/10.1371/journal.pone.0081494
Hu JS, Freeman CM, Stolberg VR, Chiu BC, Bridger GJ, Fricker SP et al (2006) AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol 169:424–432. https://doi.org/10.2353/ajpath.2006.051234
Ding C, Li J, Zhang X (2004) Bertilimumab Cambridge antibody technology Group. Curr Opin Investig Drugs 5:1213–1218
Gong H, Qi H, Sun W, Zhang Y, Jiang D, Xiao J et al (2012) Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists. Molecules 17:9961–9970. https://doi.org/10.3390/molecules17089961
Qi H, Zheng Y, Xu E, Guo C, Zhang Y, Sun Q et al (2012) An antagonist for CCR4 alleviates murine allergic rhinitis by intranasal administration. Int Arch Allergy Immunol 159:297–305. https://doi.org/10.1159/000337455
Zheng Y, Guo C, Zhang Y, Qi H, Sun Q, Xu E et al (2011) Alleviation of murine allergic rhinitis by C19, a C-terminal peptide of chemokine-like factor 1 (CKLF1). Int Immunopharmacol 11:2188–2193. https://doi.org/10.1016/j.intimp.2011.09.017
Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I et al (2006) A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 317:244–250. https://doi.org/10.1124/jpet.105.097048
Gu X, Xiao F, Lu W, Xu Y, Li X, Yu C et al (2020) Nanomedicine-mediated prevention of inflammatory monocytes infiltration ameliorate ovalbumin-induced allergic rhinitis in mouse model. Autoimmunity 53:218–224. https://doi.org/10.1080/08916934.2020.1750009
Nibbs RJ, Graham GJ (2013) Immune regulation by atypical chemokine receptors. Nat Rev Immunol 13:815–829. https://doi.org/10.1038/nri3544
Bonecchi R, Graham GJ (2016) Atypical chemokine receptors and their roles in the resolution of the inflammatory response. Front Immunol 7:224. https://doi.org/10.3389/fimmu.2016.00224
Acknowledgements
We thank Dr. Xiaofeng Yu for discussions and suggestions for the project.
Funding
This work was supported by the National Natural Science Foundation of China (81902133) to Dr. Yajing Fu.
Author information
Authors and Affiliations
Contributions
ZL and YF wrote the manuscript based on discussions with SY and prepared the table. YJ revised and examined the manuscript. All authors contributed to the article and approved the submitted version.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, Z., Yu, S., Jiang, Y. et al. Chemokines and chemokine receptors in allergic rhinitis: from mediators to potential therapeutic targets. Eur Arch Otorhinolaryngol 279, 5089–5095 (2022). https://doi.org/10.1007/s00405-022-07485-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-022-07485-6